SynthesisFrontiers in pharmacology2026
Efficacy and safety of perioperative esketamine for postoperative depressive symptoms in breast cancer patients: a meta-analysis.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative depressive symptoms may impair recovery and quality of life in patients undergoing breast cancer surgery. Esketamine has shown potential antidepressant and analgesic effects in the perioperative setting. This meta-analysis evaluated the efficacy and safety of perioperative esketamine for postoperative depressive symptoms in patients undergoing breast cancer surgery. Methods: PubMed, Embase, Cochrane Library, Web of Science, CNKI, and WanFang were systematically searched from database inception to 18 May 2026. Randomized controlled trials comparing perioperative esketamine with control interventions in patients undergoing breast cancer surgery were included. The primary outcome was postoperative depressive symptom score. Secondary outcomes included postoperative pain scores and adverse events. Random-effects models were used as the primary analytical approach. Risk of bias and certainty of evidence were assessed using the RoB 2 tool and the GRADE approach, respectively. Results: Fifteen randomized controlled trials involving 1,515 patients were included. Perioperative esketamine was associated with significantly lower postoperative depressive symptom scores at postoperative day 1 (SMD = -0.78, 95% CI: -1.08 to -0.48), postoperative day 3 or 48-72 h (SMD = -1.07, 95% CI: -1.63 to -0.51), postoperative day 7 (SMD = -0.79, 95% CI: -1.10 to -0.49), and long-term follow-up (SMD = -1.16, 95% CI: -1.68 to -0.64). For postoperative pain, esketamine was associated with lower postoperative pain scores at postoperative day 1 or 24 h (MD = -0.66, 95% CI: -1.11 to -0.21) and postoperative day 3 or 48-72 h (MD = -0.66, 95% CI: -1.09 to -0.23), but not at postoperative day 7. However, substantial heterogeneity and wide prediction intervals were observed for pain outcomes. The incidences of nausea and vomiting, postoperative delirium, and dizziness did not differ significantly between the esketamine and control groups. The certainty of evidence ranged from low to very low across outcomes. Conclusion: Perioperative esketamine may reduce postoperative depressive symptom scores and provide short-term analgesic benefits in patients undergoing breast cancer surgery. However, substantial heterogeneity, methodological limitations, and low to very low certainty of evidence warrant cautious interpretation. Further high-quality randomized trials are needed. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD420251173178, identifier CRD420251173178.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.